NEW YORK (GenomeWeb News) – KineMed today reported the Michael J. Fox Foundation has awarded it an additional $1.2 million to continue development of kinetic biomarkers for Parkinson's disease.

The biomarkers are being developed for use by drug companies to accelerate the development of treatments for the ailment and to reduce the cost of clinical trials for treatments.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The partially reinstated US travel ban leaves space for uncertainty for researchers, Nature News says.

Researchers find a number of traits differ by sex and could affect mouse model studies, according to Reuters.

Tweaking the skin microbiome could help address some skin conditions, the New York Times reports.

In PNAS this week: DNA methylation profiles of tumor tissue, gene dynamics in prokaryotes, and more.